Gallbladder cancer
Drug research and approvals for gallbladder cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 48 studies of gallbladder cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 48
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Incidental Gallbladder Carcinoma :Incidence and Clinical Significance in Specimens From Routine Cholecystectomies in…NCT07885800 · Not reported · Sohag University · starts Sep 20, 2026
- Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or CholangiocarcinomaNCT07780838 · Phase 2 · Ohio State University Comprehensive Cancer Center · starts Nov 1, 2026
- Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct TumorsNCT07726446 · Phase 2 · Tianjin Medical University Cancer Institute and Hospital · starts Oct 1, 2026
- Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract CancerNCT07641036 · Phase 1 / Phase 2 · Beijing Biotech · starts Mar 2, 2026
- Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder…NCT07636824 · Phase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · starts Jun 16, 2026
- Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract CancerNCT07614061 · Phase 1 · Shanghai Zhongshan Hospital · starts May 1, 2026
- To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With…NCT07594964 · Phase 1 · Shenzhen Xinhe Biomedical · starts Aug 25, 2025
- TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk PatientsNCT07480785 · Not applicable · Zhejiang University · starts Jan 16, 2026
- Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating RoomNCT07473687 · Not reported · Taipei Veterans General Hospital, Taiwan · starts Jan 8, 2026
Phase 3 6
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- CisplatinDNA inhibitor
- OxaliplatinDNA inhibitor
- CapecitabineThymidylate synthase inhibitor
- Porfimer sodiumDNA inhibitor
- SomatostatinSomatostatin receptor agonist
Phase 2 12 of 41
- FluorouracilThymidylate synthase inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- Leucovorin
- LapatinibReceptor protein-tyrosine kinase erbB-2 inhibitor
- PaclitaxelTubulin inhibitor
- TrastuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- MK-2206Serine/threonine-protein kinase AKT inhibitor
- Bintrafusp alfaProgrammed cell death 1 ligand 1 binding agent
- CarboplatinDNA inhibitor
- CetuximabEpidermal growth factor receptor erbB1 inhibitor
Phase 1 or earlier 5
- PemetrexedThymidylate synthase inhibitor
- UCN-01Cyclin-dependent kinase 2 inhibitor
- Motexafin gadoliniumThioredoxin reductase 1 inhibitor
- Octanoic acid
- Edodekin alfa
How its trials ended
207 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 48 whose ending is known, 23% met their primary endpoint, 15% missed it and 63% stopped early.
- Completed, result not reported7838%
- Ongoing5527%
- Status unknown2613%
- Stopped: other or unclear136%
- Met its primary endpoint115%
- Missed its primary endpoint73%
- Stopped: enrollment or feasibility73%
- Stopped: sponsor or business decision52%
- Stopped: lack of efficacy21%
- Stopped: funding21%
- Stopped: safety1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA